TR
Traws Pharma, Inc.
TRAW · NASDAQ
$0.54 -5.72% (-$0.03)
1M -2.99%
Market Cap $8.16M
P/E Ratio 0.89x
Div. Yield -
ROE -
Bulios Fair Price
$0.65
21.3% upside
Current Price
$0.54
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TRAW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
87 /100
Cheap P/S 2.93x
P/E 0.89x
P/B N/A
Growth
100 /100
Growing Rev. growth 131.12%
FCF growth N/A
Book val. growth N/A
Profitability
40 /100
Moderate Net margin 328.67%
Op. margin 640.68%
FCF margin 744.44%
Quality
83 /100
Excellent ROA 86.37%
Asset turnover 0.26x
ROIC 3,379.02%
Debt
20 /100
High Current ratio 0.72x
Int. coverage N/A
Net debt/EBITDA N/A
Stability
9 /100
Unstable Rev. volatility 655.01%
EPS volatility 80.25%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TRAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain D. Dukes
Employees
7
Headquarters
Newtown
Upcoming events
12 NOV
Earnings
Upcoming earnings report